ESKD can lead to hypocalcemia and/or hyperphosphatemia, stimulating excessive PTH secretion, causing secondary hyperparathyroidism, further exacerbating calcium and phosphate imbalance, forming a vicious circle, causing metabolic bone disease and calcification of arteries and other tissues. Here, PTH is linked to secondary hyperparathyroidism.